Effect of Micronization on Panax notoginseng: In Vitro Dissolution and In Vivo Bioavailability Evaluations

Table 5

The pharmacokinetic parameters of notoginsenosides following 540 mg/kg intragastric administration of PNP treated at different temperatures (n = 6)

Notoginsenoside	Sample (°C)	Cmax (ng/mL)	Tmax (h)	t1/2 (h)	MRT (h)	AUC0-T (ng h/mL)	AUC0-∞ (ng h/mL)
R1	30	572.15 ± 3.00	5.67 ± 0.82	7.99 ± 3.92	17.77 ± 1.70	7580.39 ± 1242.09	7716.85 ± 1259.98
	40	1390.85 ± 652.91	0.54 ± 0.10	49.37 ± 22.02	20.35 ± 1.27	13164.57 ± 1381.68	25703.83 ± 5377.46
	50	796.67 ± 98.29	1.93 ± 1.26	6.21 ± 0.32	17.27 ± 0.75	12599.54 ± 1698.24	13159.87 ± 1263.91
	100	824.20 ± 86.07	1.33 ± 0.52	42.03 ± 27.99	8.62 ± 0.65	2580.91 ± 378.24	3388.29 ± 951.55
Rg1	30	4223.25 ± 5.32	0.23 ± 0.05	4.31 ± 0.54	9.37 ± 1.38	14825.41 ± 1107.87	17920.93 ± 2148.99
	40	4469.58 ± 2181.84	0.46 ± 0.10	30.04 ± 13.17	18.75 ± 0.97	39965.99 ± 4336.01	58687.93 ± 12288.43
	50	2982.75 ± 610.15	2.01 ± 1.24	4.51 ± 0.44	15.81 ± 0.96	40506.20 ± 6170.47	40542.23 ± 6159.83
	100	2665.42 ± 378.99	1.33 ± 0.52	7.13 ± 4.56	9.51 ± 0.84	10354.88 ± 1599.79	10495.51 ± 1490.15
Rb1	30	245.16 ± 62.15	1.17 ± 0.41	8.51 ± 7.08	15.60 ± 2.63	1951.25 ± 358.41	2619.71 ± 1138.15
	40	295.87 ± 82.18	0.54 ± 0.10	36.26 ± 5.61	22.05 ± 1.09	6462.73 ± 830.14	14491.60 ± 7236.11
	50	381.11 ± 158.24	2.67 ± 1.03	21.15 ± 13.78	21.15 ± 1.29	9138.96 ± 3314.69	24329.15 ± 14404.06
	100	345.88 ± 51.91	10.17 ± 4.49	35.85 ± 15.84	14.49 ± 6.22	6103.76 ± 328.86	9846.49 ± 1855.47

Sample 30, 40, 50, and 100°C correspond to the PNP treated at different hydrothermal temperatures. , , versus 100°C.